NetworkNewsBreaks

ThursdayJan 05, 2017 10:45 am

NetworkNewsBreaks – How Caladrius Biosciences, Inc. (NASDAQ: CLBS) is Tackling Type 1 Diabetes Mellitus

Autoimmune diseases cost the U.S. more than $100 million annually. Immune tolerance happens, among other things, from the suppression of self-reactive T effector cells and auto-antigen presenting cells by T-regulatory (Treg) cells. A deficit of T-regulatory cells can lead to serious allergic and autoimmune diseases, such as Type 1 diabetes mellitus (T1DM). Caladrius Biosciences (NASDAQ: CLBS) uses T Regulatory Cell Technology to increase autologous T-regulatory cells and function, representing the potential for "true disease modification." The company is developing a therapy based on this technology (CLBS03) for the treatment of T1DM. After announcing positive results for a phase 1 study…

Continue Reading

WednesdayJan 04, 2017 2:28 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 4, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: INVE 16.86% – News: Hirsch FICAM solution wins two categories in GSN Awards APVO 11.22% – News: Resumes manufacturing of IXINITY; forecasts new supply in Q2 CATB 10.67% – News: Positive pre-clinical research on CAT-1004 program published in JCI Insight FHCO 8.15% – News: Receives outstanding payment of $2.8M from Brazilian Ministry of Health EFOI 7.46%– News: LED lighting products are first in the United States to be UL-verified with less than 1% flicker…

Continue Reading

WednesdayJan 04, 2017 12:28 pm

NetworkNewsBreaks – Concordia International Corp.’s (NASDAQ: CXRX) Shares Buoyed by Agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL)

Concordia International (NASDAQ: CXRX) is trading nearly 4% higher a day after the pharmaceutical company announced its three-year, co-promotion agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL) to expand sales of Donnatal®, Concordia's product used in the treatment of irritable bowel syndrome. Per the agreement, RedHill will aim to increase the promotion of Donnatal® among U.S. doctors who treat irritable bowel syndrome. Additionally, RedHill will incur the sales and marketing costs while Concordia will provide materials and samples. Marketing efforts are anticipated to begin during the current quarter. "This agreement is a cost-effective approach to promoting Donnatal® in a manner consistent…

Continue Reading

WednesdayJan 04, 2017 12:25 pm

NetworkNewsBreaks – Finjan Holdings, Inc. (NASDAQ: FNJN) Shares Continue Rally on Licensing Agreement, Record Revenues of $18M

Shares of cybersecurity provider Finjan Holdings (NASDAQ: FNJN) are up 9%, continuing a rally on yesterday’s news that the company’s Finjan, Inc. subsidiary is closing a Confidential Patent License Agreement with F5 Networks, Inc. The company also reported record revenues stemming from initiatives to lower costs and maximize efficiencies. "The F5 license agreement is meaningful as it is the first under our enhanced licensing program initiated to streamline efforts, reduce costs and improve efficiencies. As a result of our enforcement efforts we closed a record year at Finjan with more than $18 million in revenue, an almost four-fold increase over…

Continue Reading

WednesdayJan 04, 2017 12:22 pm

NetworkNewsBreaks – Inventergy Global, Inc. (NASDAQ: INVT) Kicks-off Patent Licensing Campaign for GTX Corp (GTXO) Technology

IP licensing and innovation company Inventergy Global (NASDAQ: INVT) this morning said its subsidiary, Inventergy Innovations, LLC,  has launched a patent licensing campaign for GTX Corp (OTC: GTXO) for its wireless location-based services IP assets based on two-way GPS tracking. As a follow-up to a definitive agreement announced in June 2016, the licensing campaign will provide substantial discounts for early adoption, multi-year commitments or higher volumes of products to companies interested in the Comm. Protocol family. "In our Inventergy Innovations model we obtain exclusive rights to license or sell a partner's patents, technology or in some cases their entire company. We use…

Continue Reading

WednesdayJan 04, 2017 12:18 pm

NetworkNewsBreaks – Bellerophon Therapeutics, Inc. (NASDAQ: BLPH): FDA Approves Protocol Changes for Phase 3 INOpulse Program, Shares Tick Higher

Bellerophon Therapeutics (NASDAQ: BLPH) this morning said the U.S. FDA has approved proposed modifications to the company’s phase 3 program for INOpulse in Pulmonary Arterial Hypertension (PAH). The protocol changes have the potential to reduce the time to market and are expected to result in “substantial” costs savings. “We are gratified that the FDA has agreed with the proposed modifications to our PAH Phase 3 program, which have the potential to make INOpulse available to PAH patients approximately two years earlier than otherwise would have been possible under the original Phase 3 program,” Bellerophon president and CEO Fabian Tenenbaum stated…

Continue Reading

WednesdayJan 04, 2017 12:15 pm

NetworkNewsBreaks – Evoke Pharma, Inc. (NASDAQ: EVOK) Shares Surge on Positive Data from Phase 3 Gimoti Study

Shares of Evoke Pharma (NASDAQ: EVOK) are 35% higher in morning trade after the company reported positive data from its phase 3 trial of Gimoti for symptomatic relief of acute and recurrent diabetic gastroparesis. While the study failed to reach its primary endpoint, Gimoti “significantly” reduced nausea and abdominal pain in moderate to severe patients. Evoke notes that the results are consistent with FDA guidance on the clinical evaluation of drugs used to treat gastroparesis. “As our discussions with the FDA progressed over the past few months, we have continued to analyze data from our Phase 3 trial of Gimoti…

Continue Reading

TuesdayJan 03, 2017 1:21 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 3, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: HDYN 16.51% – News: Signed agreement with Schlumberger to provide essential drilling services TISA 14.38% – News: Named new chairman of its board of directors XBIO 11.63% – News: CEO to present at the Biotech Showcase™ conference January 9 in San Francisco MDGS 5.84% – News: Presenting at the Innovation in Gastroenterology, 2017 Symposium on January 4 LWLG 7.90%– News: Released shareholder update APRI 6.15% – News: Announced changes in executive management CAFN 6.40%…

Continue Reading

TuesdayJan 03, 2017 1:17 pm

NetworkNewsBreaks – Bridgeline Digital, Inc.’s (NASDAQ: BLIN) iAPPS Product Suite Helps Businesses Enhance Digital Assets

Today’s companies increasingly rely on the effectiveness of digital assets for a variety of business functions. Websites, mobile applications and online stores, for example, are now the most powerful marketing tools available. Focusing on digital values, Bridgeline Digital (NASDAQ: BLIN) offers interactive technology solutions designed to enhance a company's web properties. Its iAPPS product suite is a digital engagement platform that incorporates everything from web content management and eCommerce to digital marketing and web analytics. Recently, the iAPPS product suite was chosen by one of the world’s largest engine manufacturers to power its eCommerce website. It allows the company to…

Continue Reading

TuesdayJan 03, 2017 1:11 pm

NetworkNewsBreaks – Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Obtains Orphan Drug Designation for Fragile X Syndrome Treatment

Marinus Pharmaceuticals (NASDAQ: MRNS) this morning said that the FDA has granted Orphan Drug Designation to the company’s CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome, the most common genetic cause of autism, which is caused by a mutation in the FMR1 gene. This designation provides Marinus with a seven-year period of U.S. marketing exclusivity, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act filing fees. “We are pleased to receive Orphan Drug Designation from the…

Continue Reading